Retatrutide vs Wegovy: Head-to-Head Comparison

Triple agonist retatrutide vs single agonist Wegovy (semaglutide). Which delivers better weight loss?

Quick Comparison

Feature Retatrutide Wegovy
Weight Loss 24-28.7% 10-15%
Mechanism Triple agonist Single agonist (GLP-1)
Availability 2027-2028 Available now
Brand Cost $900-1,400/mo (est) $900-1,400/mo
Compounded Cost Unknown $179-349/mo

Weight Loss: Retatrutide Wins

Retatrutide: 24-28.7% average weight loss (up to 71 lbs for a 240-lb person)

Wegovy: 14.9% average weight loss (~36 lbs for a 240-lb person)

Retatrutide delivers nearly DOUBLE the weight loss due to its triple-agonist mechanism.

Availability: Wegovy Wins

Wegovy is available NOW:

Retatrutide is 1-2 years away:

Side Effects: Similar

Both medications share GI side effects due to GLP-1 activation:

Wegovy advantage: More real-world data means we know exactly what to expect. Retatrutide is newer with less long-term safety information.

Cost: Wegovy Wins (Compounded)

Wegovy brand-name: $900-1,400/month without insurance

Compounded semaglutide: $179-349/month through telemedicine (available NOW)

Retatrutide pricing: Unknown but expected to match Wegovy brand pricing. Compounded availability uncertain.

Which Should You Choose?

Choose Retatrutide If:

Choose Wegovy/Semaglutide If:

The Practical Answer

Start Wegovy (compounded semaglutide) NOW:

Why wait? You'll be healthier NOW instead of staying overweight until 2028. You can always switch medications later.

Start Semaglutide (Wegovy Alternative) for $179/Month

Same active ingredient as Wegovy. Available now through telemedicine.

Start with MEDVi →

Related: Retatrutide vs Tirzepatide | What Is Retatrutide?

⚠️
Medical Disclaimer: This article is for informational purposes only and does not provide medical advice. GLP-1 medications require a prescription and should be used only under the guidance of a licensed healthcare professional. Always consult your doctor before starting any weight loss medication to ensure it is safe for your specific health history.